Urothelial Cancer
A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001
- Details
ClinicalTrials.gov ID:
NCT03219333
Diagnosis Type:
NA
USOR Number:
17005
- Address
433 SW 10th Street
Ocala, FL 34471
P: (352) 732-4032